- Active not recruitingPHASE2
A Study to Evaluate the Efficacy and Safety of JCAR017 in Adult Subjects With Relapsed or Refractory Indolent B-cell Non-Hodgkin Lymphoma (NHL)
This study is testing a new cell therapy called JCAR017 for adults with certain types of non-Hodgkin lymphoma that has returned or hasn't responded to other treatments. It aims to see how well it works and if it's safe.
For: Lymphoma, Non-HodgkinUnited States · Austria · Canada - RecruitingPHASE1
A Study to Evaluate the Safety, Tolerability, Efficacy, and Drug Levels of CC-97540 in Participants With Relapsing Forms of Multiple Sclerosis, Progressive Forms of Multiple Sclerosis or Refractory Myasthenia Gravis (MG) (Breakfree-2)
This study is looking at a new drug called CC-97540 for people with certain types of Multiple Sclerosis (MS) or a muscle weakness condition called Myasthenia Gravis (MG). We want to see if it's safe, how well people can handle it, and if it helps their condition.
For: Multiple Sclerosis · Myasthenia GravisUnited States · Belgium · France - RecruitingPHASE1, PHASE2
Study of KITE-363 or KITE-753 in Participants With Relapsed and/or Refractory B-cell Lymphoma
This study looks at new treatments, KITE-363 and KITE-753, for B-cell lymphoma that has come back or not responded to previous treatments. It aims to see how safe and effective these new drugs are for patients.
For: Relapsed and/or Refractory B-cell LymphomaUnited States · Australia · Canada - Active not recruitingPHASE2
Master Protocol to Assess the Safety and Antitumor Activity of Genetically Engineered T Cells in NY-ESO-1 and/or LAGE-1a Positive Solid Tumors
This study looks at a new treatment called lete-cel for certain advanced cancers like synovial sarcoma and myxoid/round cell liposarcoma. It uses specially modified immune cells to fight cancer, testing how safe and effective it is for people with specific cancer markers.
For: NeoplasmsUnited States · Canada · France - Ongoing, recruitingTherapeutic confirmatory (Phase III)
Tisagenlecleucel versus standard of care in adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphoma: A randomized, open label, phase III trial (BELINDA)
This study compares a new cell therapy (Tisagenlecleucel) with standard treatments for adults with an aggressive type of lymphoma that has come back or not responded to previous therapy. Researchers want to see which treatment is better at stopping the cancer from growing.
For: Adult patients with relapsed or refractory aggressive B-cell non-Hodgkin lymphomaNetherlands · Spain · Norway - Active not recruitingPHASE3
A Study to Compare the Efficacy and Safety of Idecabtagene Vicleucel With Lenalidomide Maintenance Therapy Versus Lenalidomide Maintenance Therapy Alone in Adult Participants With Newly Diagnosed Multiple Myeloma Who Have Suboptimal Response After Autologous Stem Cell Transplantation
This study compares a new cell therapy (ide-cel) plus standard maintenance medicine (lenalidomide) against lenalidomide alone for adults with newly diagnosed multiple myeloma. It's for those who haven't fully responded to their initial stem cell transplant.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study to Compare Axicabtagene Ciloleucel With Standard of Care Therapy as First-line Treatment in Participants With High-risk Large B-cell Lymphoma
This study compares a new treatment, axicabtagene ciloleucel, with standard care for adults recently diagnosed with high-risk large B-cell lymphoma. It aims to see if the new treatment works better as a first treatment option.
For: High-risk Large B-cell Lymphoma (LBCL)United States · Australia · Austria - RecruitingPHASE2
A Study of CC-97540 (BMS-986353 or Zola-cel), CD19-Targeted NEX-T CAR T Cells, in Participants With Active SLE Despite Immunosuppressants (Breakfree-SLE)
This study is testing a new cell therapy called CC-97540 for people with lupus and lupus kidney disease. It aims to see if it's safe and effective when other treatments haven't worked well enough.
For: Lupus Erythematosus, Systemic · Lupus NephritisUnited States · Argentina · Austria - Active not recruitingPHASE2
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Treated Advanced (Metastatic or Unresectable) Synovial Sarcoma or Myxoid/Round Cell Liposarcoma
This study looks at a new cell therapy called Lete-Cel for certain advanced cancers like synovial sarcoma and myxoid/round cell liposarcoma. It aims to see how safe and effective this treatment is for people whose cancer hasn't responded to previous treatments.
For: NeoplasmsUnited States · Canada · France - RecruitingPHASE1
A Study to Test the Safety, Tolerability and Effect of ZI-MA4-1 for Patients With Locally Advanced or Metastatic Solid Malignancies
This study is testing a new cell therapy called ZI-MA4-1 for certain advanced cancers like ovarian, lung, and head and neck cancer. It's the first time this treatment designed to fight cancer will be given to people, aiming to see if it's safe and how well it works.
For: Ovarian Cancer · Squamous Non-Small Cell Lung Cancer (NSCLC) · Synovial SarcomasUnited Kingdom - RecruitingPHASE3
A Study Comparing Anitocabtagene Autoleucel to Standard of Care Therapy in Participants With Relapsed/ Refractory Multiple Myeloma
This study compares a new treatment called anitocabtagene autoleucel with standard care for people with multiple myeloma that has come back or not responded to previous treatments. It aims to see if the new treatment works better.
For: Multiple MyelomaUnited States · Australia · Austria - Active not recruitingPHASE3
Study of Axicabtagene Ciloleucel Versus Standard of Care Therapy in Participants With Relapsed/Refractory Follicular Lymphoma
This study is looking at a new treatment called axicabtagene ciloleucel for follicular lymphoma that has come back or hasn't responded to other treatments. It compares this new treatment to standard care to see how well it works.
For: Relapsed/Refractory Follicular LymphomaUnited States · France · Germany - Active not recruitingPHASE3
A Study of Bortezomib, Lenalidomide and Dexamethasone (VRd) Followed by Cilta-cel, a CAR-T Therapy Directed Against BCMA Versus VRd Followed by Lenalidomide and Dexamethasone (Rd) Therapy in Participants With Newly Diagnosed Multiple Myeloma for Whom ASCT is Not Planned as Initial Therapy
This study looks at new treatments for multiple myeloma, a type of blood cancer. It compares a standard treatment plus a new cell therapy called cilta-cel, against the standard treatment alone, for people newly diagnosed who aren't having a stem cell transplant initially.
For: Multiple MyelomaUnited States · Argentina · Australia - Active not recruitingPHASE3
A Study of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Ciltacabtagene Autoleucel Versus Daratumumab, Bortezomib, Lenalidomide and Dexamethasone (DVRd) Followed by Autologous Stem Cell Transplant (ASCT) in Participants With Newly Diagnosed Multiple Myeloma
This study compares two treatments for newly diagnosed multiple myeloma. One treatment uses a drug combination followed by a cell therapy (Cilta-cel). The other uses the same drug combination followed by a stem cell transplant. The aim is to see which works best.
For: Multiple MyelomaUnited States · Australia · Belgium - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy B – Relapsed/Refractory Richter Transformation (RT)
This study looks at a new cell therapy called Tecartus for adults with a type of blood cancer called Richter Transformation that has come back or not responded to previous treatments. It aims to see how well it works and if it's safe.
For: Relapsed/refractory Richter Transformation (RT)France · Germany · Spain - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA 25) – Substudy C – Relapsed/Refractory Burkitt Lymphoma (BL)
This study is looking at a new treatment called Tecartus for adults in the UK with a specific type of blood cancer called Burkitt Lymphoma. It's for patients whose cancer has come back or hasn't responded to previous treatments. Researchers want to see how well Tecartus works.
For: Relapsed/Refractory Burkitt Lymphoma (BL)Netherlands · France · Austria - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy D - Relapsed/Refractory Hairy Cell Leukemia (HCL)
This study looks at a new cell therapy called Tecartus for adults with a rare blood cancer called hairy cell leukaemia. It aims to see how well it works and if it's safe for people whose cancer has come back or hasn't responded to previous treatments.
For: Relapsed/Refractory Hairy Cell LeukemiaNetherlands · Spain · Sweden - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, Open-Label, Multicenter, Basket Study Evaluating the Safety and Efficacy of Brexucabtagene Autoleucel in Adults with Rare B-cell Malignancies (ZUMA-25) – Substudy A – Relapsed/Refractory Waldenstrom Macroglobulinemia
This study is testing a new cell therapy called Tecartus for adults in the UK with a rare blood cancer called Waldenstrom Macroglobulinemia. It's for people whose cancer has come back or hasn't responded to previous treatments. We want to see how well it works and if it's safe.
For: Relapsed/Refractory Waldenstrom Macroglobulinemia (WM)Netherlands · Spain · Germany - Ongoing, recruitingTherapeutic exploratory (Phase II)
A PHASE 2 MULTICENTER STUDY OF AXICABTAGENE CILOLEUCEL IN SUBJECTS WITH RELAPSED/REFRACTORY INDOLENT NON-HODGKIN LYMPHOMA (INHL)
This study looks at a new type of cell therapy, Yescarta, for people with certain types of slow-growing non-Hodgkin lymphoma that has come back or hasn't responded to other treatments. Researchers are checking how well it works and if it's safe over many years.
For: Follicular Lymphoma · Marginal Zone Lymphoma · Indolent Non-Hodgkin LymphomaFrance - AuthorisedTherapeutic exploratory (Phase II)
A multi-center single arm Phase II study to evaluate the safety and efficacy of genetically engineered autologous cells expressing anti-CD20 and anti-CD19 specific chimeric antigen receptor in subjects with relapsed and/or refractory diffuse large B cell lymphoma
This study looks at a new type of cell therapy, called MB-CART2019.1, for people with a specific type of lymphoma that has come back or hasn't responded to other treatments. It checks how safe and effective it is.
For: Relapsed/refractory diffuse large B cell lymphoma (R-R DLBCL)Hungary · Croatia - Active not recruitingPHASE2, PHASE3
A Trial of Treatments to Assess the Effects on Outcome of Adults With AML and MDS Undergoing Allogeneic SCT
This study looks at new treatments for adults with acute myeloid leukaemia (AML) and high-risk myelodysplastic syndrome (MDS) who are having a stem cell transplant. It aims to improve transplant success and reduce relapse.
For: Acute Myeloid Leukaemia · High-risk Myelodysplastic SyndromeUnited Kingdom - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986353 (Zolacabtagene- Autoleucel / Zola-cel), CD19-CAR T Cells, Versus Standard of Care in Participants With Active Systemic Sclerosis
This study looks at a new treatment called BMS-986353 for severe Systemic Sclerosis. It compares this new treatment with standard care to see if it's more effective and safe for people with this condition.
For: Systemic SclerosisUnited States · Belgium · Canada - RecruitingPHASE1
A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
This study is testing a new medicine called FT819 for serious autoimmune diseases like lupus and vasculitis. It's looking at how safe it is and how well it works to reduce disease activity, especially in those who haven't responded to other treatments.
For: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) · Idiopathic Inflammatory Myositis (IIM) · Systemic Sclerosis (SSc)United States · France · Sweden - RecruitingPHASE3
International Randomised Phase III Clinical Trial in Children With Acute Myeloid Leukaemia
This study looks at new ways to treat children with a type of blood cancer called Acute Myeloid Leukaemia (AML). It compares different chemotherapy drugs, including a drug called gemtuzumab ozogamicin, and different types of stem cell transplants to find the most effective and safest treatments for young patients.
For: Acute Myeloid LeukaemiaAustralia · France · Ireland - AuthorisedTherapeutic exploratory (Phase II)
A phase 2, Multicenter Study of TILs Treatment in Germ Cell tumors: the ARES Study
This study is looking at a new treatment for certain types of advanced germ cell tumours that haven't responded to standard chemotherapy. It uses a type of immunotherapy where a patient's own immune cells are specially treated to fight the cancer, combined with other medicines.
For: Germ Cell Tumors refractory to salvage chemotherapySpain - Active not recruitingPHASE2
A Comparison of Reduced Dose Total Body Irradiation (TBI) and Cyclophosphamide With Fludarabine and Melphalan Reduced Intensity Conditioning in Adults With Acute Lymphoblastic Leukaemia (ALL) in Complete Remission. (ALL-RIC)
This study compares two ways to prepare adults with acute lymphoblastic leukaemia (ALL) for a stem cell transplant. It aims to find out if a slightly stronger treatment can better stop the cancer from coming back, without making the transplant recovery harder.
For: Acute Lymphoblastic LeukemiaUnited Kingdom - Ongoing, recruitingTherapeutic exploratory (Phase II)
A Phase 2, multicenter, open-label study of lifileucel (tumor-infiltrating lymphocytes [TIL]) in participants with previously treated advanced melanoma
This study is looking at a new treatment called lifileucel for people with advanced melanoma that has already been treated. It's an early-stage study to see how well the treatment works and if it's safe. It uses your own immune cells to fight the cancer.
For: Previously treated advanced melanomaFrance · Italy · Germany - AuthorisedTherapeutic exploratory (Phase II)
Revumenib Treatment in Combination with FLA Chemotherapy in Paediatric Refractory/Relapsed KMT2A-r, NUP98-r or NPM1-mut Acute Myeloid Leukemia (AML)
This study is testing a new drug called Revumenib with standard chemotherapy for children and young people with a type of blood cancer called Acute Myeloid Leukaemia (AML). It's for those whose cancer has returned after treatment or hasn't responded to initial therapy.
For: Acute Myeloid LeukemiaDenmark · Italy · Czechia - RecruitingPHASE3
A Study to Compare the Efficacy and Safety of BMS-986393 Versus Standard Regimens in Adult Participants With Relapsed or Refractory and Lenalidomide-exposed Multiple Myeloma (QUINTESSENTIAL-2)
This study compares a new treatment called BMS-986393 with standard medicines for adults with multiple myeloma that has come back or not responded to previous treatment, including lenalidomide. We want to see if the new medicine works better and is safe.
For: Relapsed or Refractory Multiple Myeloma (RRMM)United States · Argentina · Australia - Active not recruitingPHASE2
Study to Evaluate Safety and Antitumor Activity of Lete-Cel (GSK3377794) in HLA-A2+ Participants With NY-ESO-1 Positive Previously Untreated Advanced (Metastatic or Unresectable) Synovial Sarcoma and Myxoid/Round Cell Liposarcoma
This study is looking at a new T-cell therapy called Lete-Cel for people with advanced synovial sarcoma or myxoid/round cell liposarcoma. It aims to see how safe and effective this treatment is in fighting these cancers.
For: NeoplasmsUnited States · Canada · France